Clinical trials: Neoplasms by Site
Breast Cancer
Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
The gemcitabine-paclitaxel and gemcitabine-platinum combinations have shown promise in the treatments of MBC; however, the optimal dosing schedules for these combinations have not yet been determined.
- Trial name
- NCT00191854
- Testing
- gemcitabine, paclitaxel, carboplatin
- Where
- 18 sites in Brazil, China and 4 more
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), achieved by HX008 or Investigator's Choice Chemotherapy in participants with Microsatellite Instability High…
- Trial name
- NCT05652894
- Testing
- HX008(Pucotenlimab), Investigator's Choice Chemotherapy
- Where
- 63 sites in China
- Volunteers
- 190 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Breast Cancer
APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)
This study will compare the anti-tumor efficacy of apricoxib and lapatinib/capecitabine with placebo and lapatinib/capecitabine as measured by time to disease progression and evaluate urinary PGE-M measurements or baseline COX-2…
- Trial name
- APRiCOT-B (NCT00657137)
- Testing
- apricoxib + lapatinib + capecitabine
- Where
- 44 sites in United States
- Volunteers
- 12 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.
- Trial name
- CAPAFOUR (NCT04990037)
- Testing
- CAN04, FOLFIRINOX
- Where
- 9 sites in France, Spain
- Volunteers
- 25 people
- Sponsor
- Cantargia AB
Non Small Cell Lung Cancer
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response.
- Trial name
- TroFuse-019 (NCT06312137)
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Cisplatin
- Where
- 270 sites in United States, Argentina and 29 more
- Volunteers
- 780 people
- Sponsor
- Merck Sharp & Dohme LLC
Thyroid Cancer
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.
- Trial name
- NCT00098345
- Testing
- ZD6474 (vandetanib)
- Where
- 6 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Breast Cancer Stage IIIA, Breast Cancer, Stage IIIB
Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer
Our study evaluates the use of Laser-Assisted Immunotherapy (LIT) plus placebo and LIT plus low-dose cyclophosphamide versus that of Standard of Care in patients presenting with Stage IIIA, IIIB or IV breast cancer.
- Conditions
- Breast Cancer Stage IIIA, Breast Cancer, Stage IIIB, Breast Cancer Stage IV
- Trial name
- NCT03202446
- Testing
- 1% Glycated Chitosan, Photothermal Laser, Cyclophosphamide
- Where
- 4 sites in Peru
- Volunteers
- 18 people
- Sponsor
- Eske Corporation S.A.C
Hepatocellular Carcinoma
A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
The purpose of this phase Ib study is to assess the safety, tolerability and effectiveness of IBI318 in combination with conventional TACE (cTACE) in patients with potentially resected hepatocellular carcinoma.
- Trial name
- NCT04635527
- Testing
- IBI318, cTACE
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Oncolytic Virotherapy
Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact
Purpose of the study is to evaluate the safety, tolerability and pharmacokinetic parameters of the drug based on double recombinant vaccinia virus VV-GMCSF-Lact, in patients with recurrent/refractory metastatic breast cancer in…
- Trial name
- NCT05376527
- Testing
- Double Recombinant Vaccinia Virus VV-GMCSF-Lact
- Where
- 4 sites in Russia
- Volunteers
- 34 people
- Sponsor
- "Oncostar" LLC
Carcinoma, Renal Cell
Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
The purpose of this study is to determine if orally-administered recombinant human lactoferrin is effective in the treatment of advanced renal cell carcinoma (RCC) in patients who have failed at least one prior systemic therapy…
- Trial name
- NCT00095186
- Testing
- Recombinant Human Lactoferrin
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Agennix
Non Small Cell Lung Cancer
Assessment of Video Assisted Thoracoscopic Surgery (VATS) Versus Open Surgery for Patients Undergoing Lobectomy
Assessment of VATS versus standard open surgery for treatment of non small cell lung cancer.
- Trial name
- NCT00912366
- Testing
- Lobectomy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Medtronic - MITG
Endometrial Cancer
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy.
- Trial name
- NCT05797831
- Testing
- Navtemadlin
- Where
- 83 sites in United States, Austria and 15 more
- Volunteers
- 268 people
- Sponsor
- Kartos Therapeutics, Inc.
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Cervical Cancer
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical…
- Trial name
- NCT04982237
- Testing
- AK104, paclitaxel, carboplatin
- Where
- 5 sites in China
- Volunteers
- 445 people
- Sponsor
- Akeso
Hormone Sensitive Prostate Cancer, Prostate Cancer
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.
- Conditions
- Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- Trial name
- NCT02319837
- Testing
- Enzalutamide, Leuprolide Open Label
- Where
- 255 sites in United States, Australia and 15 more
- Volunteers
- 1,068 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy.
- Trial name
- NCT07489495
- Testing
- Belzutifan, Zanzalintinib
- Where
- 106 sites in United States, Argentina and 17 more
- Volunteers
- 758 people
- Sponsor
- Merck Sharp & Dohme LLC
Central Nervous System Tumors
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
This study consists of 2 parts: Dose Escalation Part 1 and Dose Expansion Part 2. The Dose Escalation Part 1 will evaluate the safety and tolerability of Avelumab in combination with Lenvatinib and determine the recommended…
- Trial name
- NCT05081180
- Testing
- Avelumab, Lenvatinib
- Where
- 9 sites in Canada, France and 2 more
- Volunteers
- 17 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Malignant Melanoma
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
This randomized, open-label, two period crossover study will evaluate the effect of food on the pharmacokinetics of a single dose of RO5185426 and the efficacy and safety of continuous administration in patients with BRAF V600E…
- Trial name
- NCT01264380
- Testing
- RO5185426
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with…
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms
- Trial name
- NCT04543188
- Testing
- PF-07284890, Binimetinib, Midazolam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Prostate Cancer, Castration Resistant
Multi-academic Center Study of Xofigo Patients
The study will be conducted from a real-world perspective to describe treatment sequences involving radium-223 and chemotherapy in patients with metastatic castrate resistant prostate cancer (mCRPC) and assess overall survival…
- Trial name
- NCT03419442
- Testing
- Xofigo, Taxotere, Jevtana
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.